TCM
KROS icon

TCG Crossover Management’s Keros Therapeutics KROS Stock Holding History

TCG Crossover Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-550,000
Closed -$6.39M – 38
2024
Q4 		$8.71M Sell
550,000
-329,344
-37% -$17.1M 0.85% 31
2024
Q3 		$51.1M Hold
879,344
– – 4.33% 8
2024
Q2 		$40.2M Hold
879,344
– – 4.19% 9
2024
Q1 		$58.2M Buy
+879,344
New +$52.1M 4.6% 8

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCG Crossover Management's KROS Position: Q1 2025 in Review

TCG Crossover Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 550,000 shares — an estimated $6.39M sold.

TCG Crossover Management first reported a position in KROS in Q1 2024 and held it in 4 quarters. The position peaked at $58.2M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • TCG Crossover Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • TCG Crossover Management sold 550,000 Keros Therapeutics shares in Q1 2025, an estimated $6.39M.
  • TCG Crossover Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 4 quarters.
  • TCG Crossover Management's Keros Therapeutics position peaked at $58.2M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on TCG Crossover Management's 13F filing for Q1 2025, filed 14 May 2025.